

WO 2004/037211


PCT/US2003/034083

CLAIMS

5 What is claimed is:

1. A metabolite of 3'-*tert*-butyl-3'-N-*tert*-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel of formula Ia or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof

10



wherein the substituents are as defined in the following table


<u>Metabolite Code</u>	<u>R1</u>	<u>R2</u>	<u>R3</u>	<u>R4</u>	<u>C9</u>
M1	SG	H	CH ₃	OH	C=O
M2	SG	OH	CH ₃	H	C=O
M4 & M5	SG	H	CH ₃	H	C=O
M6	OCH ₃	OH	CH ₃	OH	C=O
M7	OH	OCH ₃	CH ₃	OH	C=O
M8	OH	H	CH ₃	OH	C=O
M8A	H	H	CH ₃	(OH) ₂	C=O
M9	H	H	CH ₃	H	(CH)OH

WO 2004/037211


PCT/US2003/034083

M10	H	H	CH ₃	OH	C=O
M11	H	H	COOH	H	C=O
M12	H	H	CH ₃	OH	C=O
M13	H	H	CH ₃	H	C=O

and



5
2. A metabolite of 3'-*tert*-butyl-3'-N-*tert*-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel of formula Ib or a pharmaceutically acceptable salt, solvate or prodrug thereof



Ib

wherein the substituents are as defined in the following table


Metabolite Code	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
M14	H	H	CH ₃	CH ₃	H	20
M15	SG	H	CH ₃	CH ₃	H	H
M16	H	H	CH ₃	CH ₃	H	20

WO 2004/037211

PCT/US2003/034083


M17	H	H	CH ₃	CH ₃	OH	H
M18	H	OH	CH ₃	CH ₃	OH	H
M19	H	H	CH ₃	CH ₃	OH	H
M20	H	H				H
M21	H	H				H
M22	H	H	CH ₃	COOH	H	H
M23	H	H	CH ₃	CH ₃	OH	H
M24	H	H	COOH	CH ₃	H	H

and



wherein the side chains on M20 and M21 are as shown below:


5



3. A metabolite of 3'-*tert*-butyl-3'-N-*tert*-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel of formula Ic or a pharmaceutically acceptable salt, solvate or prodrug thereof

WO 2004/037211

PCT/US2003/034083



]c


5 wherein the substituents are as defined in the following table:

<u>Metabolite Code</u>	<u>R₁</u>	<u>R₂</u>	<u>R₃</u>	<u>R₄</u>	<u>C₉</u>	<u>C₁₃</u>
M9	CH ₃	H	CO(CH ₃)	CO(OCH ₃)	(CH)OH	(CH)OH
M10	CH ₃	OH	CO(CH ₃)	CO(OCH ₃)	C=O	(CH)OH
M10A	CH ₃	H	H	CO(OCH ₃)	C=O	(CH)OH
M11	COOH	H	CO(CH ₃)	CO(OCH ₃)	C=O	(CH)OH
M10B	CH ₃	OH	CO(CH ₃)	CO(OCH ₃)	C=O	(CH)OH
M10C	CH ₃	H	CO(CH ₂ OH)	CO(OCH ₃)	C=O	(CH)OH
M12	CH ₃	OH	CO(CH ₃)	CO(OCH ₃)	C=O	(CH)OH
M13	CH ₃	H	CO(CH ₃)	CO(OCH ₃)	C=O	(CH)OH
M13A	CH ₃	H	H	CO(OCH ₃)	C=O	C=O
M13B	CH ₃	OH	CO(CH ₃)	H	C=O	(CH)OH
M13C	CH ₃	H	CO(CH ₃)	CO(OCH ₃)	C=O	(CH)OH
M13D	CH ₃	H	CO(CH ₃)	CO(OCH ₃)	C=O	C=O

4. A metabolite of 3'-*tert*-butyl-3'-N-*tert*-butyloxycarbonyl-4-deacetyl)-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel of formula Id or a pharmaceutically acceptable salt, solvate or prodrug thereof

WO 2004/037211

PCT/US2003/034083



1d

wherein the substituents are as defined in the following table:

<u>Metabolite</u> <u>Code</u>	R ₁	R ₂	R ₃	R ₄	R ₅
M15B	CO(CH ₃)	CH ₂ OH or COOH		H	H
M17	CO(CH ₃)	CH ₃	CH ₃	H	OH
M18B	H	CH ₃	COOH	H	H
M19	CO(CH ₃)	CH ₃	CH ₃	H	OH
M19A	H	COOH	CH ₃	H	H
M22	CO(CH ₃)	CH ₃	COOH	H	H
M23	CO(CH ₃)	CH ₃	CH ₃	H	OH
M24	CO(CH ₃)	COOH or CH ₃	CH ₃ or COOH	H	H
M23A	CO(CH ₃)	CH ₃	CH ₃	OH or H	H or OH
M23B	CO(CH ₃)	CH ₃	CH ₃	OH	H
M23C	CO(CH ₃)	CH ₃	CH ₃	OH or H	H or OH
M26	H	CH ₃	CH ₃	H	H
M23D	CO(CH ₃)	CH ₃	CH ₃	OH	H

WO 2004/037211

PCT/US2003/034083

M27 CO(CH₃) CH₃ CH₃ H H

5. A pharmaceutical composition comprising a metabolite according to Claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier, vehicle or diluent.

6. A pharmaceutical composition comprising a metabolite according to Claim 2 or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier, vehicle or diluent.

10 7. A pharmaceutical composition comprising a metabolite according to Claim 3 or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier, vehicle or diluent.

15 8. A pharmaceutical composition comprising a metabolite according to Claim 4 or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier, vehicle or diluent.

9. A method for inhibiting tumor growth in a mammalian host which comprises administering to said mammal a tumor-growth inhibiting amount of a compound as defined in Claim 1.

10. A method for inhibiting tumor growth in a mammalian host which comprises administering to said mammal a tumor-growth inhibiting amount of a compound as defined in Claim 2.

25 11. A method for inhibiting tumor growth in a mammalian host which comprises administering to said mammal a tumor-growth inhibiting amount of a compound as defined in Claim 3.

WO 2004/037211

PCT/US2003/034083

12. A method for inhibiting tumor growth in a mammalian host which comprises administering to said mammal a tumor-growth inhibiting amount of a compound as defined in Claim 4.